BLS Pharmaceuticals (ASX:BLS) Accounts Payable & Accrued Expense: A$7.40 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:BLS BLS Pharmaceuticals Ltd ASX:BLS
46 GF Score
Price A$0.92
GF Value A$0.71
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is BLS Pharmaceuticals Accounts Payable & Accrued Expense?

BLS Pharmaceuticals ASX:BLS +1.66% 46 Accounts Payable & Accrued Expense is A$7.40 Mil as of Dec. 2025. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.71 (Modestly Overvalued). The stock has 6 warning signs investors should review.

BLS Pharmaceuticals's quarterly accounts payable & accrued expense declined from Dec. 2024 (A$6.24 Mil) to Jun. 2025 (A$5.83 Mil) but then increased from Jun. 2025 (A$5.83 Mil) to Dec. 2025 (A$7.40 Mil).

BLS Pharmaceuticals's annual accounts payable & accrued expense increased from Jun. 2023 (A$2.62 Mil) to Jun. 2024 (A$2.66 Mil) and increased from Jun. 2024 (A$2.66 Mil) to Jun. 2025 (A$5.83 Mil).

BLS Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for BLS Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BLS Pharmaceuticals Accounts Payable & Accrued Expense Chart

BLS Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.96 2.62 2.66 5.83

BLS Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 2.66 6.24 5.83 7.40
ASX:BLS
46GF Score
BLS Pharmaceuticals Ltd ASX:BLS
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BLS Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of A$7.40 Mil mean?
BLS Pharmaceuticals (ASX:BLS) has a Accounts Payable & Accrued Expense of A$7.40 Mil as of Dec. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on BLS Pharmaceuticals and its competitors.
Is BLS Pharmaceuticals' Accounts Payable & Accrued Expense too high?
BLS Pharmaceuticals' current Accounts Payable & Accrued Expense is A$7.40 Mil. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Accounts Payable & Accrued Expense compare to VRTX and REGN?
BLS Pharmaceuticals' Accounts Payable & Accrued Expense of A$7.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on BLS Pharmaceuticals and its competitors. BLS Pharmaceuticals's current Accounts Payable & Accrued Expense is A$7.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.71, compared to a current price of A$0.92 — trading 29.6% above its estimated fair value. The current Accounts Payable & Accrued Expense is A$7.40 Mil. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Accounts Payable & Accrued Expense is A$7.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?

Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued. The current stock price of A$0.92 is trading 29.6% above its estimated GF Value™ of A$0.71. GuruFocus considers BLS Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ASX:BLS:

  • Accounts Payable & Accrued Expense: A$7.40 Mil
  • GF Value™: A$0.71 vs. price of A$0.92 (29.6% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BLS Pharmaceuticals Business Description

Other Exchanges PR80:Germany
Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score

Get the complete analysis for ASX:BLS

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.92
Price
A$0.71
GF Value